|
1
|
Dahl E, Gluud LL, Kimer N and Krag A:
Meta-analysis: The safety and efficacy of vaptans (tolvaptan,
satavaptan and lixivaptan) in cirrhosis with ascites or
hyponatraemia. Aliment Pharmacol Ther. 36:619–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kawaratani H, Fukui H and Yoshiji H:
Treatment for cirrhotic ascites. Hepatol Res. Jul 1–2016.(Epub
ahead of print).
|
|
3
|
Kurosaki M and Izumi N: Tolvaptan for the
Treatment of Refractory Ascites. Intern Med. 55:2909–2910. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakaida I, Kawazoe S, Kajimura K, Saito T,
Okuse C, Takaguchi K, Okada M and Okita K; ASCITES-DOUBLEBLIND
Study Group, : Tolvaptan for improvement of hepatic edema: A phase
3, multicenter, randomized, double-blind, placebo-controlled trial.
Hepatol Res. 44:73–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sakaida I, Nakajima K, Okita K, Hori M,
Izumi T, Sakurai M, Shibasaki Y, Tachikawa S, Tsubouchi H, Oka H,
et al: Can serum albumin level affect the pharmacological action of
tolvaptan in patients with liver cirrhosis? A post hoc analysis of
previous clinical trials in Japan. J Gastroenterol. 50:1047–1053.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Londoño MC, Cárdenas A, Guevara M, Quintó
L, de Las Heras D, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo
V and Ginès P: MELD score and serum sodium in the prediction of
survival of patients with cirrhosis awaiting liver transplantation.
Gut. 56:1283–1290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iwamoto T, Maeda M, Hisanaga T, Saeki I,
Fujisawa K, Matsumoto T, Hidaka I, Ishikawa T, Takami T and Sakaida
I: Predictors of the Effect of Tolvaptan on the Prognosis of
Cirrhosis. Intern Med. 55:2911–2916. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kogiso T, Yamamoto K, Kobayashi M,
Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E and Tokushige
K: Response to tolvaptan and its effect on prognosis in cirrhotic
patients with ascites. Hepatol Res. 47:835–844. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akiyama S, Ikeda K, Sezaki H, Fukushima T,
Sorin Y, Kawamura Y, Saitoh S, Hosaka T, Akuta N and Kobayashi M:
Therapeutic effects of short- and intermediate-term tolvaptan
administration for refractory ascites in patients with advanced
liver cirrhosis. Hepatol Res. 45:1062–1070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohki T, Sato K, Yamada T, Yamagami M, Ito
D, Kawanishi K, Kojima K, Seki M, Toda N and Tagawa K: Efficacy of
tolvaptan in patients with refractory ascites in a clinical
setting. World J Hepatol. 7:1685–1693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Komiyama Y, Kurosaki M, Nakanishi H,
Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M,
Gotou T, et al: Prediction of diuretic response to tolvaptan by a
simple, readily available spot urine Na/K ratio. PLoS One.
12:e01746492017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamada T, Ohki T, Hayata Y, Karasawa Y,
Kawamura S, Ito D, Kojima K, Seki M, Toda N and Tagawa K: Potential
Effectiveness of Tolvaptan to Improve Ascites Unresponsive to
Standard Diuretics and Overall Survival in Patients with
Decompensated Liver Cirrhosis. Clin Drug Investig. 36:829–835.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Umemura T, Shibata S, Sekiguchi T,
Kitabatake H, Nozawa Y, Okuhara S, Kimura T, Morita S, Komatsu M,
Matsumoto A and Tanaka E: Serum sodium concentration is associated
with increased risk of mortality in patients with compensated liver
cirrhosis. Hepatol Res. 45:739–744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Angeli P, Wong F, Watson H and Ginès P:
CAPPS Investigators: Hyponatremia in cirrhosis: Results of a
patient population survey. Hepatology. 44:1535–1542. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kamath PS, Wiesner RH, Malinchoc M,
Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER and Kim
WR: A model to predict survival in patients with end-stage liver
disease. Hepatology. 33:464–470. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Imamura T, Kinugawa K, Shiga T, Kato N,
Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, et al:
Novel criteria of urine osmolality effectively predict response to
tolvaptan in decompensated heart failure patients-association
between non-responders and chronic kidney disease. Circ J.
77:397–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan HK, James PD, Sniderman KW and Wong F:
Long-term clinical outcome of patients with cirrhosis and
refractory ascites treated with transjugular intrahepatic
portosystemic shunt insertion. J Gastroenterol Hepatol. 30:389–395.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsusaki K, Ohta K, Yoshizawa A and Gyoda
Y; Japanese CART Study Group, : Novel cell-free and concentrated
ascites reinfusion therapy (KM-CART) for refractory ascites
associated with cancerous peritonitis: Its effect and future
perspectives. Int J Clin Oncol. 16:395–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kario K: Key Points of the Japanese
Society of Hypertension Guidelines for the Management of
Hypertension in 2014. Pulse Basel. 3:35–47. 2015. View Article : Google Scholar : PubMed/NCBI
|
